Skip to main content
Premium Trial:

Request an Annual Quote

Millipore Posts 40-Percent Gain in Q1 Sales, Though Profits Sink 23 Percent

NEW YORK (GenomeWeb News) — Millipore yesterday said first-quarter revenues increased 39 percent as R&D spending rose 50 percent and profit slid 23 percent.
 
Total receipts for the three months ended March 31 increased to $372 million from $268.4 million year over year.
 
Sales in the company’s Bioprocess segment rose 40 percent to $214.3 million, while Bioscience revenue swelled 51 percent to $157.7 million.
 
In a statement, CEO Martin Madaus said demand was strong for its drug-related and vaccine-related consumables in the Bioprocess division, and the Bioscience division is focused on integrating Serologicals, which the company acquired last summer.
  
R&D spending increased to $27.5 million from $18.4 million year over year.
 
The company said profits fell to $26.7 million from $34.5 million in the year-ago period.
 
Millipore said it had around $56.6 million in cash and cash equivalents as of March 31.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.